Lab Insights
Seven semaglutide specimens tested this year: six verified, one 14% under label.
Semaglutide remains the most-tested compound in our program. The 2026 mid-year picture: identity confirmed on all seven specimens (no counterfeits), purity uniformly above 96.8%, and one significant content shortfall — a Sterling Compound Co. product measuring 14% under label.
The absence of counterfeits in this cycle contrasts with retatrutide, where verification failure remains materially more common. Full reports for each specimen are in the testing database.
Apex Peptides holds the top position; Cascade Research Group drops 17 points after failed verification; BioRegen enters the top five.
RankingsThe August guidance clarifies bulk-substance eligibility and signals enforcement priorities for the next year.
RegulationAbsorption enhancers push oral bioavailability past thresholds previously considered impractical for large peptides.
ResearchThe Peptide Institute Weekly
One email a week: new study summaries, the latest independent lab results, ranking movements, and regulatory developments that matter.
